Oral Glucocorticosteroid in the Treatment of Severe Asthma Exacerbation in Hospitalized Patients
Information source: Hamamatsu University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Intervention: methylprednisolone sodium succinate (mPSL) (Drug); prednisolone (PSL) (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Hamamatsu University Official(s) and/or principal investigator(s): Kingo Chida, MD,PhD, Study Chair, Affiliation: Hamamatsu University
Summary
A comparison of oral prednisolone administration with intravenous methylprednisolone
infusion in the treatment of acute asthma exacerbation in hospitalized patients. Oral
glucocorticosteroids administration may be effective as intravenous high-dose
methylprednisolone infusion.
Clinical Details
Official title: Phase 4, Randomized Study of Oral Glucocorticosteroid Administration in the Treatment of Acute Severe Asthma Exacerbation in Hospitalized Patients
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Efficacy of oral prednisolone for the treatment of acute asthma
Secondary outcome: The safety of oral prednisolone for the treatment of acute asthma
Eligibility
Minimum age: 16 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Asthma patients, who need hospitalized treatment, who do not respond with initial
treatment including bronchodilator and IV methylprednisolone therapy
Exclusion Criteria:
- Need for incubation
- With severe complications
- Received systemic glucocorticosteroid therapy in the previous 4 weeks
Locations and Contacts
Hamamatsu University School of Medicine, Hamamatsu, Japan
Additional Information
Starting date: June 2007
Last updated: September 5, 2011
|